

Allosteric mechanisms in normal and pathological nicotinic acetylcholine receptors

Jean-Pierre Changeux* and Stuart J Edelstein†

Recent chemical and advanced structural studies on site-directed and naturally occurring pathological mutants of individual members of the multigene family of nicotinic acetylcholine receptors have yielded structure–function relationships supporting indirect ‘allosteric’ interactions between the acetylcholine-binding sites and the ion channel in signal transduction.

Addresses

*Laboratoire de Neurobiologie Moléculaire, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France; e-mail: changeux@pasteur.fr
†Département de Biochimie, Université de Genève, 30 quai Ernest-Ansermet, CH-1211 Geneva 4, Switzerland; e-mail: stuart.edelstein@biochem.unige.ch

Current Opinion in Neurobiology 2001, 11:369–377

0959-4388/01/\$ – see front matter

© 2001 Elsevier Science Ltd. All rights reserved.

Abbreviations

ADNFLE autosomal dominant nocturnal frontal lobe epilepsy
nAChR nicotinic acetylcholine receptor

Introduction

Membrane receptors for transmitters, peptides and pharmacological agents are central to signal transduction. They selectively recognize chemical effectors (neuronal or hormonal) and transduce, in an ‘indirect’ allosteric manner [1], binding recognition into biological action through the activation of ligand-gated ion channels (LGICs) and/or G-protein-coupled receptors (GPCRs). Since their initial isolation and characterization in the early 1970s as integral membrane proteins, about 2000 different receptor species have been cloned and sequenced. In the *C. elegans* genome, for example, there are up to 90 LGIC genes, and about 5% of all *C. elegans* genes encode a GPCR, including about 1000 orphan receptors that may be chemoreceptors [2]. Many of these receptor genes are conserved through evolution [3]. About 5% of the known human genes are assigned to receptors, which are the targets of major drugs, and are responsible for several important human pathologies.

In this review, we discuss new insights gained in the much studied model provided by the nicotinic acetylcholine receptor (nAChR), and in addition make reference to recent observations made in other systems concerning general receptor mechanisms.

With respect to neurotransmitter signaling, the classical example of the neuromuscular junction — where ACh is liberated in less than 0.2 ms as a high local concentration pulse (up to 10^{-3} M) over a postsynaptic dense layer of nAChR molecules — may not be as general as initially thought. Acetylcholine, as well as other neurotransmitters

and peptides, may be released in a volume or paracrine mode [4] at the level of varicosities, thus modulating, in a ‘tonic’ manner, a widely dispersed population of high-affinity receptors. For example, in the spinal cord, endogenous ACh tonically modulates serotonin release, in part through nAChRs present on inhibitory γ -amino butyric acid (GABA)ergic neurons [5].


Subunit composition and distribution of neuronal nAChR

Nicotinic acetylcholine receptors exist as ‘homopentamers’ made up of $\alpha 7$, $\alpha 8$ or $\alpha 9$ subunits, or ‘heteropentamers’ comprising various combinations of $\alpha 2$ – $\alpha 6$ with $\beta 2$ – $\beta 4$ subunits, $\alpha 9$ with $\alpha 10$ subunits, or precisely arranged $(\alpha 1)_2$ – $\beta 1$ – γ / ϵ – δ subunits in muscle. (For the latest findings, see articles in the special issues of *Eur J Pharmacol* 393:1–320 [2000], and *Neuropharmacology* 39:2515–2855 [2000], as well as the *Soc Neurosci Abstr* [2000].)

New subunit combinations have been discovered recently by Groot-Kormelink *et al.* [6] in experiments using a *ménage-à-trois* reporter mutation in $\beta 3$ to detect interactions with the $\alpha 3\beta 4$ couple. Similarly, modified single-channel properties of $\alpha 3$ and $\beta 2$ or $\beta 4$ have been observed by Nelson and Lindstrom [7*] in the presence of $\alpha 5$, and $\alpha 6$ has been found to interact with various combinations of α (including $\alpha 5$) and β subunits [8,9]. Activity changes also have revealed interactions of $\alpha 7$ with $\beta 3$ [10*]. Specific subunit combinations were revealed by single-cell PCR in conjunction with electrophysiological recordings in the locus ceruleus, possibly $\alpha 6\beta 3\beta 2(\alpha 4)$ [11], and in the substantia nigra and ventral tegmental area, where non- $\alpha 7$ -containing receptors with a putative $\alpha 4\alpha 6\alpha 5(\beta 2)_2$ composition were found to be sensitive to 1 nM methyllycaconitine [12].

The distribution of nAChR proteins in the brain may not resemble the highly clustered localization at the motor endplate, where a number of specific proteins (e.g. AGRIN, 43K rapsyn, MuSK, MASC) have been identified and shown to interact with postsynaptic nAChR using mouse gene knockouts (for review see [13]). However, none of these proteins has been implicated directly in modulating the signaling response, although mice with a knockout of the nAChR ϵ subunit have revealed that the receptor may have an indirect role in maintaining the highly ordered structure of the postsynaptic membrane [14]. Direct evidence for subsynaptic clustering of neuronal nAChR has been obtained in chick ciliary ganglion [15,16,17*], and for the $\alpha 4$ subunit in the substantia nigra [18,19]. It is plausible that as yet unidentified cytoplasmic proteins resembling gephyrin [20,21] or PSD-95 [22*] for glycine or glutamate receptors, respectively, may be found to interact with neuronal nAChRs.

Figure 1



Representation of the ligand-binding site and the ion channel. (a) Ligand-binding site, as viewed from the exterior of the receptor along the plane of the membrane. Residues identified by affinity labeling and site-directed mutagenesis are indicated in the primary site present on α -type subunits and the complementary site present on γ or δ subunits of muscle receptor, or on α subunits of homopentameric neuronal receptors or β subunits of heteromeric neuronal receptors (for additional information, see [1,32]); the schematic arrangement of the loops is consistent with the recent structural studies (K Brejc *et al.*, personal communication). (b) Ion channel. Residues from M2 and the cytoplasmic loop component implicated in the selectivity filter are presented; adapted from [32].

In the brain, many nAChR have been localized at presynaptic positions [23] where they facilitate neurotransmitter release by allowing the calcium ion entry directly through

the nicotinic channels, or indirectly through voltage-sensitive calcium channels [24]. Presynaptic nAChRs might also mediate local neuromodulation by ACh at the level of 'synaptic triads' [25], which are postulated to serve as elementary components for temporal learning. For example, in the hippocampus, the nAChR can modulate neural circuits by exciting inhibitory interneurons [26] or by reducing the responsiveness of *N*-methyl D-aspartate (NMDA) glutamate receptors [27].

Structure–function relations updated

Our current understanding of the nAChR molecule is based mainly on chemical and genetic approaches combined with predictive methods and the limited structural information available. The success in determining the three-dimensional structure of the binding region of a glutamate receptor [28,29] — with the details largely anticipated by models based on homologies with bacterial periplasmic binding proteins [30] — underlies the predictive capacities of secondary structure computations from first principles, for which the most advanced methods have been applied recently to the nAChR by Le Novère *et al.* [31]. The final consensus secondary structure includes 9 α helices and 17 β strands: the large extracellular domain is predicted to comprise β strands with only two α helices at the α -amino group end, with resemblance to the immunoglobulin domain [32]; the transmembrane segments are predicted to be in a mixed α/β topology, with the α helices predominantly linked, on the cytoplasmic side, through a stretch of variable length and sequence to two well-conserved amphipathic helices whose function deserves investigation.

The location of the 'agonist binding sites' at the interface between subunits where each subunit provides three loops of amino-acid residues, A, B and C for the principal, and D, E and F for the complementary component, respectively (see Figure 1a), is supported by recent data (see [32]). The cation– π interactions that stabilize agonist binding have been investigated by Zhong *et al.* [33], who used tryptophan derivatives (as well as a tethered quaternary ammonium group) incorporated into the receptor by an *in vivo* nonsense-suppression method [33]. The orientation requirements for activation by covalent agonists have been provided by Sullivan and Cohen [34], who used ligands tethered via cysteine substitution in conjunction with sulfhydryl-reactive reagents. Striking differences in the environment of the two ACh sites carried by the muscle nAChR have been revealed by a novel method of time-resolved fluorescence spectroscopy [35]. Improved definition of the residues in the amino-terminal domain involved in desensitization [36] has emphasized the contribution of a short loop in the vicinity of the main immunogenic region in conferring fast desensitization from the β 2 to the β 4 subunit [37].

The crystal structure at 2.7 Å resolution of the acetylcholine-binding domain from a novel glia-derived soluble analogue of the neuronal nAChR synaptic domain that

occurs naturally in the snail *Lymnaea stagnalis* (AB Smit *et al.*, personal communication) reveals a homopentameric organization, with the ACh (and α toxin) site made up of the predicted aromatic amino acids and double cysteine of loops A, B, C and D, E, F at the subunit interface, and with each monomer folding, as anticipated [32], into an immunoglobulin-like topology with long and twisted β -strands (K Brejc *et al.*, personal communication).

New insights into the functional organization of the channel by site-directed mutagenesis distinguish the transmembrane M2 α -helical component, which lines a hydrophilic pore (independently of the charge on the amino-acid chains), from an SF loop (which may be analogous to a phosphate or 'P' loop), which serves as a 'selectivity filter' at (or near) the cytoplasmic extremity of the channel (see Figure 1b) [38**], but also possibly as a gate [39]. This role is also confirmed by mutations that convert the glycine receptor from anionic to cationic selectivity [40]. These results take on added importance in relation to the K^+ channel, the structure of which has been determined by X-ray crystallography [41], which shares possible geometric features with the nAChR ion channel, although in an inverted disposition [32].

As in the case of the K^+ channel, the direct participation of backbone atoms in establishing the properties of the channel should be considered. In this respect, of particular relevance is England *et al.*'s [42**] study of backbone mutations in transmembrane regions M1 and M2. These authors used a nonsense suppression technique using α -hydroxy (rather than α -amino) acids to replace the usual peptide backbone bond by an ester.

Unwin and co-workers [43**] have obtained 4.6-Å resolution electron microscopy images of *Torpedo* nAChR, which now attach to the receptor cytoplasmic domain (on the basis of five-fold symmetry organization) densities formerly interpreted as belonging to 43K rapsyn. This suggests — still hypothetically — that there is ion flow through slits adjacent to the two α subunits, with the M3–M4 loop contributing charged residues that might influence selectivity (α subunit residues E377, E384, E391 and E398).

Production of chimeric γ - ϵ subunits has revealed that elements of the γ subunits in the M3–M4 region can influence the open times of channels in excised patches [44]. Several myasthenic syndrome mutants with altered functional properties have also been reported in the M3–M4 region (see below), as well as a deletion that alters subunit interactions [45*], suggesting that this portion of the molecule also participates in intersubunit contacts. The 4.6-Å resolution data for subunit organization continue to be interpreted by England *et al.* [43**] as the β subunit located between the two α subunits, although the bulk of the available evidence places the γ subunit between the two α subunits [45*,46].

In any case, the structure–function studies demonstrate unambiguously that the ACh-binding site and the ion

channel belong to distinct and far distant domains, and thus that their interaction is indirect or allosteric.

Modes and models of signal transduction

Single nAChR molecules respond to ACh by undergoing a conformational transition to an open-channel state, associated with slower 'modulatory' transitions to (or from) desensitized states. These properties are readily described by an allosteric model (see Figure 2a) that is based on concerted transitions between pre-existing conformational states (implying a mechanism involving 'rigid body motion') [1]. Nevertheless, because of their simplicity, standard sequential models of two ACh bindings followed by a gating transition (implying a mechanism involving 'plastic motion') are still used to fit experimental data, as in several recent examples [44,47,48]. In certain cases a variant involving mono-liganded gating is also invoked [48]. In our opinion, four sets of experimental data strongly argue in favor of transitions between a small number of conformations that exist prior to ligand binding.


First, observations on the distance separating the ion channel and the ACh-binding site in the range of 20–40 Å [43**,49]; these data confirm that a direct contact is not possible and that coupling of binding and channel opening must occur by an indirect allosteric-type mechanism.

Second, pleiotropic phenotypes for which a single-point mutation in the channel domain increases the apparent affinity for agonists at the distant ACh-binding site, such as the myasthenic mutant ϵ T264P; the data are quantitatively accounted for by an allosteric mechanism assuming a decrease of the isomerization constant from 10^9 to 10^3 between basal and active states [50].

Third, spontaneous openings of single nAChR channels recorded by voltage clamp in the absence of ligand [51,52]; the data can only be described by an allosteric model that includes opening of unliganded receptors [50]; spontaneous openings in muscle and neuronal nAChR with mutations in other subunits have also been reported recently [53*].

Fourth, conversion of competitive agonists to competitive antagonists, as first observed in the nAChR $\alpha 7$ mutant L247T [54] (or vice-versa, as in the case of glycine receptors with a startle disease mutation [55]). Both phenotypes are readily understood in the allosteric framework, but not in the sequential one [1]. (Similar properties have recently been reported by Taverna *et al.* [56**] for the Lurcher mutation that enhances potency of glutamate and converts an antagonist to an agonist.) In addition, for the γ subunit W55L mutant (of *Torpedo*), *d*-tubocurarine (*d*'TC) binding at the α - γ site acts not as a competitive antagonist but as a coactivator or partial agonist [57]. The data can be accounted for by an allosteric model that assumes that the γ subunit W55L mutation alters ACh binding at the α - γ but not at the α - δ site, while *d*'TC binding to both sites is unaltered

Figure 2



Allosteric models for enzymes and membrane receptors. (a) The initial formulation of the allosteric model, in terms of a dimeric enzyme (used with permission from [103]).

(b) Tyrosine receptor kinase, showing aggregation of monomers to form inactive and active dimers; the latter are preferentially stabilized by ligand (adapted from [62]).

(c) The two domains (D1 and D2) contributing to the GluR2 ligand-binding core; the domains (lobes) undergo rotation and closure of the site that is stabilized by smaller agonist and opposed by larger antagonist (adapted from [29]). (d) Extracellular ligand-binding region of the mGluR1 receptor; two domains (lobes) are present, as in (c), identified as LB1 and LB2 with closer contact of the domains stabilized by glutamate (adapted from [61]).

(SJ Edelman and JB Cohen, unpublished data). In principle, direct tests of mechanistic alternatives (such as the 'induced fit') could be provided in experiments that independently monitor single-binding and single-channel events [58], but experimental obstacles need to be overcome first.

In contrast, results interpreted as being in conflict with the allosteric scheme have been reported on the basis of indirect biochemical measurements of binding [59] or conformational state [60], but in each case ambiguities concerning the nature of the measurements raise doubts about the conclusions.

Concerning other systems, structural studies by Morikawa and co-workers [61**] of the extracellular ligand-binding region of the seven-transmembrane-helix metabotropic receptor mGluR1 has revealed 'active' and 'resting' conformations (see Figure 2b) that are modulated through the dimeric interface by a packed α -helical structure, with glutamate binding stabilizing both the 'active' dimer and the closed protomer in dynamic equilibrium. In the case of the ionotropic iGluR2 ligand-binding core, dimer formation and symmetrical interdimer interaction with a large conformational change stabilized by agonists as compared with competitive antagonists is, as well, consistent with the basic concept of rigid body motion. The conformational transition would consist of changes in the quaternary organization of protein oligomers with little alteration of the protomer tertiary structure [29*], with individual domains (1 and 2) occupying in this case the roles of protomers (see Figure 2c). A scheme strictly identical to the original two-state model (see Figure 2a,d) has also been adopted by Schlessinger [62*] for signal transduction by tyrosine kinase receptors.

Functional, cooperative nearest-neighbor interactions between receptor molecules in a membrane two-dimensional lattice were suggested and formalized several decades ago [63], in an attempt to extend allosteric interactions to supra-macromolecular assemblies in biological membranes. Although up to now nAChR function has generally been analyzed in terms of individual receptor molecules (with the possible exception of dimer formation in muscle nAChR [64–66]), evidence is accumulating for many receptor systems that supramacromolecular interactions and clustering contribute to function [67*]. This is the case for bacterial chemotactic receptors, but also for the large receptor complex on T lymphocytes [68], arrays of ryanodine receptor [69], and possibly the intricate lattice of cochlear outer hair cells [70]. Evidence has been presented for molecular interactions between different receptors such as GlyR and α 3-containing nAChR clusters under one presynaptic terminal [17*]. In addition, α 3 β 4 nAChR and ATP-gated purine-mediated P2X₂ channels influence each other when co-activated [71*], although the precise mechanism of these interactions are not yet elucidated.

nAChR allosteric mutations, deletions and pathological 'states of consciousness'

Natural mutations in the human population are continuing to provide a rich source of complex and surprising phenotypes, particularly in congenital myasthenic syndromes, for which over 50 distinct mutations have been characterized, with most occurring in the ϵ subunit gene [72]. Roughly half of the well-characterized mutants fall into the category of 'gain-of-function' or 'hyperactive' phenotypes, argued above as supporting the allosteric scheme [50,51]. Moreover, in-frame duplication of six residues in the M3–M4 loops results in abnormal activation kinetics [73] and the point mutation A411P leads to a wide distribution of channel open times [48], reinforcing the arguments that

the M3–M4 loop contributes to channel regulation. The α subunit mutation V285I in the M3 domain has also been reported; this amino-acid position shows volume-dependent contributions to channel gating [74].

Concerning neuronal nAChRs, mutations in the α 4 subunit produce autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE; reviewed in [75]), although exactly how the functional changes observed in the mutant α 4 subunits cause the pathological symptoms, which result in transient alterations in consciousness, remains unclear. A β 2 missense mutation V287L in M2 that leads to a 'hyperactive' phenotype manifested by slower desensitization has also been implicated in ADNFLE [76]. Roles for α 7 have been suggested in prenatal effects of nicotine on lung cells [77], but also in Alzheimer's disease [78,79], as well as in schizophrenia [80]. In a search for sequence variations that might influence smoking behavior, five novel single nucleotide polymorphisms (SNPs) of β 2 were examined, but no correlation with nicotine use was observed [81].

Insights into the functional role of neuronal nAChR subunits have been obtained in mice from a series of knockouts involving the genes for subunits α 3, α 4, α 7, α 9, β 2 and β 4 [82]. The phenotypes observed in these mice include reduced antinociception [83*] and increased exploratory behavior [84] in mice lacking α 4; attenuated self-administration of nicotine [85] and increased neurodegeneration during aging [86] in mice lacking β 2; and various dysfunctions in mice lacking α 3 [87] or both β 2 and β 4 [88]. Preliminary reports for mutant knockin mice, including α 7 L247T [89] and the replacement of leucine by serine at the corresponding position in the α 4 subunit [90] offer experimental models of neurodegeneration associated with hyperactivity of nAChR.

Long-term regulation

Considerable attention has been focused recently on the phenomenon of nAChR upregulation, initially in relation to the effects of smoking [91]. Current research has used prolonged exposure to agonists for various human nAChR subunits [92–94]. Some evidence suggests that this phenomenon may be related to desensitization for α 4 β 2 receptors in oocytes [95], although in other studies on α 4 β 2 receptors in M10 cells upregulation occurred at concentrations of agonist 1–2 orders of magnitude higher than their estimated binding constants [96]. However, multiple desensitized states and differences in the kinetic of desensitization and upregulation, as well as ligand-specific differences, may complicate these analyses [97*]. Several specific phosphorylation processes have also been implicated [91].

An important issue is the fraction of agonist binding sites that are intracellular, and the values are surprisingly elevated in certain cases [96], with virtually no α 3 β 2 surface receptors detected by antibody reaction before upregulation in one report [94]. The features of upregulation that appear intimately related to trafficking in

intracellular membranes suggest a 'maturation' model (S Bohler *et al.*, personal communication) that may be related to the specific assembly pathways [98,99].

Conclusions and future prospects

Considerable progress has been made in establishing the stereochemical basis of ligand-binding and ion channel properties for nAChR in general and for the individual variations among members of the multigene family. A fairly coherent picture is emerging on the basis of algorithms for prediction of conformation [31**], medium-resolution structural studies [43**], and astute use of site-directed mutagenesis [32]. In addition, studies on the three-dimensional structure of a soluble molluscan ACh-binding protein provide important new insights (K Brejc *et al.*, personal communication).

For mechanistic studies based on the kinetics of channel opening and closing, a generally accepted framework has yet to be adopted, on the basis of structural data. In principle, the allosteric model of concerted transitions between pre-existing conformational states could serve such a role [1] and in addition would be useful in designing adequate pharmacological treatments for the many novel phenotypes appearing for congenital myasthenic syndromes [72] and ADFNLE [75,76,100].

Animal models of human pathologies are also emerging from the modification of nAChR in transgenic mice [101]. The observation that agonist-dependent upregulation may also play a major role is becoming the focus of considerable research activity in the field of nicotine addiction. At the level of integrating receptors in brain-scale processes [102], paracrine effects [4] have emerged as a plausible mechanism for globally activating receptors, for example, at presynaptic terminals [23]. In all these instances, the signal transduction properties of receptors create a critical step in the bottom-up transfer of information in neuronal networks from the molecular to the cognitive level.

Update

Evidence has been presented for narrowing of the channel involving residues above the M1–M2 loop in the desensitized state [104]. An article describing studies on mice with an $\alpha 4$ channel mutation reported in abstract form [90] has now been published [105]. Progress in analyzing the mode of $\alpha 7$ inhibition by the β -amyloid peptide has been reported by two groups [106,107]. Upregulation has now been shown to involve conductance changes in the case of $\alpha 4\beta 2$ receptors in K-177 cells [108]. Concerning the correlates of acetylcholine with consciousness, the review by Perry *et al.* remains timely reading [109].

Acknowledgements

We thank Pierre Jean Corringer for helpful comments. This work was supported by the Collège de France, the Université de Genève, the Centre National de la Recherche Scientifique, the Association Française contre les Myopathies, the Association pour la Recherche sur le Cancer and the Commission of the European Communities.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Changeux JP, Edelstein SJ: **Allosteric receptors after 30 years.** *Neuron* 1998, **21**:959-980.
2. Bargmann CI: **Neurobiology of the *Caenorhabditis elegans* genome.** *Science* 1998, **282**:2028-2033.
3. Le Novère N, Changeux JP: **The ligand gated ion channel database.** *Nucleic Acids Res* 1999, **27**:340-342.
4. Agnati LF, Zoli M, Stromberg I, Fuxe K: **Intercellular communication in the brain: wiring versus volume transmission.** *Neuroscience* 1995, **69**:711-726.
5. Cordero-Erausquin M, Changeux JP: **Tonic nicotinic modulation of serotonergic transmission in the spinal cord.** *Proc Natl Acad Sci USA* 2001, **98**:2803-2807.
6. Groot-Kormelink PJ, Luyten W, Colquhoun D, Sivilotti LG: **A reporter mutation approach shows incorporation of the 'orphan' subunit $\beta 3$ into a functional nicotinic receptor.** *J Biol Chem* 1998, **273**:15317-15320.
7. Nelson ME, Lindstrom J: **Single channel properties of human $\alpha 3$ AChRs: impact of $\beta 2$, $\beta 4$ and $\alpha 5$ subunits.** *J Physiol (Lond)* 1999, **516**:657-678.
- In single-channel measurements on human subunits expressed in oocytes or in the human neuroblastoma cell line IMR-32, differences in conductance, open times and burst lengths are observed for $\alpha 3\alpha 5\beta 4$ compared with $\alpha 3\beta 4$ alone, indicating a modulatory role for $\alpha 5$.
8. Vailati S, Hanke W, Bejan A, Barabino B, Longhi R, Balestra B, Moretti M, Clementi F, Gotti C: **Functional $\alpha 6$ -containing nicotinic receptors are present in chick retina.** *Mol Pharmacol* 1999, **56**:11-19.
9. Kuryatov A, Olale F, Cooper J, Choi C, Lindstrom J: **Human $\alpha 6$ AChR subtypes: subunit composition, assembly, and pharmacological responses.** *Neuropharmacology* 2000, **39**:2570-2590.
10. Palma E, Maggi L, Barabino B, Eusebi F, Ballivet M: **Nicotinic acetylcholine receptors assembled from the $\alpha 7$ and $\beta 3$ subunits.** *J Biol Chem* 1999, **274**:18335-18340.
- Using the $\alpha 7$ mutant L247T, the authors detect interactions with $\beta 3$ in oocytes on the basis of substantially modified properties, including single-channel conductances. The $\beta 3$ subunits may thus participate in regulating receptor function.
11. Lena C, de Kerchove D'Exaerde A, Cordero-Erausquin M, Le Novère N, del Mar Arroyo-Jimenez M, Changeux JP: **Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons.** *Proc Natl Acad Sci USA* 1999, **96**:12126-12131.
12. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP: **Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei.** *J Neurosci* 2001, **21**:1452-1463.
13. Sanes JR, Lichtman JW: **Development of the vertebrate neuromuscular junction.** *Annu Rev Neurosci* 1999, **22**:389-442.
14. Schwarz H, Giese G, Müller H, Koenen M, Witzemann V: **Different functions of fetal and adult AChR subtypes for the formation and maintenance of neuromuscular synapses revealed in ϵ -subunit-deficient mice.** *Eur J Neurosci* 2000, **12**:3107-3116.
15. Williams BM, Temburni MK, Levey MS, Bertrand S, Bertrand D, Jacob MH: **The long internal loop of the $\alpha 3$ subunit targets nAChRs to subdomains within individual synapses on neurons *in vivo*.** *Nat Neurosci* 1998, **1**:557-562.
16. Shoop RD, Martone ME, Yamada N, Ellisman MH, Berg DK: **Neuronal acetylcholine receptors with $\alpha 7$ subunits are concentrated on somatic spines for synaptic signaling in embryonic chick ciliary ganglia.** *J Neurosci* 1999, **19**:692-704.
17. Tsen G, Williams B, Allaire P, Zhou YD, Ikonomov O, Kondova I, Jacob MH: **Receptors with opposing functions are in postsynaptic microdomains under one presynaptic terminal.** *Nat Neurosci* 2000, **3**:126-132.
- This article reports on ultrastructural and functional data that reveal the presence of distinct receptor clusters for inhibitory and excitatory receptors at the same synapse on chick parasympathetic ciliary ganglion.

18. Sorenson EM, Shiroyama T, Kitai ST: **Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat.** *Neuroscience* 1998, **87**:659-673.
19. Arroyo-Jimenez MM, Bourgeois JP, Marubio LM, Le Sourd AM, Ottersen OP, Rinvik E, Fairen A, Changeux JP: **Ultrastructural localization of the $\alpha 4$ -subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra.** *J Neurosci* 1999, **19**:6475-6487.
20. Kneussel M, Betz H: **Clustering of inhibitory neurotransmitter receptors at developing postsynaptic sites: the membrane activation model.** *Trends Neurosci* 2000, **23**:429-435.
21. Meier J, Meunier-Durmort C, Forest C, Triller A, Vannier C: **Formation of glycine receptor clusters and their accumulation at synapses.** *J Cell Sci* 2000, **113**:2783-2795.
22. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Brecht DS: **PSD-95 involvement in maturation of excitatory synapses.** *Science* 2000, **290**:1364-1368.
- PSD-95 expression enhances postsynaptic clustering and activity of glutamate receptors, and increases the number and size of dendritic spines. These results suggest that PSD-95 may have roles in synapse stabilization and plasticity.
23. MacDermott AB, Role LW, Siegelbaum SA: **Presynaptic ionotropic receptors and the control of transmitter release.** *Annu Rev Neurosci* 1999, **22**:443-485.
24. Lena C, Changeux JP: **Role of Ca^{2+} ions in nicotinic facilitation of GABA release in mouse thalamus.** *J Neurosci* 1997, **17**:576-585.
25. Dehaene S, Changeux JP, Nadal JP: **Neural networks that learn temporal sequences by selection.** *Proc Natl Acad Sci USA* 1987, **84**:2727-2731.
26. Ji D, Dani JA: **Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons.** *J Neurophysiol* 2000, **83**:2682-2690.
27. Fisher JL, Dani JA: **Nicotinic receptors on hippocampal cultures can increase synaptic glutamate currents while decreasing the NMDA-receptor component.** *Neuropharmacology* 2000, **39**:2756-2769.
28. Armstrong N, Sun Y, Chen GQ, Gouaux E: **Structure of a glutamate-receptor ligand-binding core in complex with kainate.** *Nature* 1998, **395**:913-917.
29. Armstrong N, Gouaux E: **Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core.** *Neuron* 2000, **28**:165-181.
- A number of structural changes are reported to occur following agonist binding to the binding domain, including domain closure and a 180° flip of a *trans* peptide bond in the ligand-binding site.
30. Paas Y, Devillers-Thierry A, Teichberg VI, Changeux JP, Eisenstein M: **How well can molecular modelling predict the crystal structure: the case of the ligand-binding domain of glutamate receptors.** *Trends Pharmacol Sci* 2000, **21**:87-92.
31. Le Novère N, Corringer PJ, Changeux JP: **Improved secondary structure predictions for a nicotinic receptor subunit: incorporation of solvent accessibility and experimental data into a two-dimensional representation.** *Biophys J* 1999, **76**:2329-2345.
- Consensus predictions using four third-generation algorithms are calculated. The predicted secondary structure includes nine α helices (24.2% of the residues) and 17 β strands (22.5% of the residues). The large extracellular domain is predicted to be mainly composed of β strands, with two helices at the amino-terminal end. The transmembrane segments are predicted to be in a mixed α/β topology. The cytoplasmic domain is predicted to include two well-conserved amphipathic helices. In general, the segments predicted to occur in a periodic structure correspond to the more conserved regions, as defined by an analysis of sequence conservation per position performed on 152 superfamily members.
32. Corringer PJ, Le Novère N, Changeux JP: **Nicotinic receptors at the amino acid level.** *Annu Rev Pharmacol Toxicol* 2000, **40**:431-458.
33. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA: **From *ab initio* quantum mechanics to molecular neurobiology: a cation- π binding site in the nicotinic receptor.** *Proc Natl Acad Sci USA* 1998, **95**:12088-12093.
34. Sullivan DA, Cohen JB: **Mapping the agonist binding site of the nicotinic acetylcholine receptor. Orientation requirements for activation by covalent agonist.** *J Biol Chem* 2000, **275**:12651-12660.
- An elegant method is used to explore the binding site by introducing cysteine residues at critical positions and testing the effect of primary or quaternary amines tethered covalently. This leads to a model of the orientation of the quaternary ammonium in the agonist binding site.
35. Martinez KL, Corringer PJ, Edelman SJ, Changeux JP, Merola F: **Structural differences in the two agonist binding sites of the Torpedo nicotinic acetylcholine receptor revealed by time-resolved fluorescence spectroscopy.** *Biochemistry* 2000, **39**:6979-6990.
- Changes in fluorescence lifetimes of dansyl-C6-choline bound to Torpedo nAChR observed with *d*-tubocurarine binding are exploited to characterize differences in the two binding sites.
36. Corringer PJ, Bertrand S, Bohler S, Edelman SJ, Changeux JP, Bertrand D: **Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors.** *J Neurosci* 1998, **18**:648-657.
37. Bohler S, Gay S, Bertrand S, Corringer PJ, Edelman SJ, Changeux JP, Bertrand D: **Desensitization of neuronal nicotinic acetylcholine receptors conferred by N-terminal segments of the $\beta 2$ subunit.** *Biochemistry* 2001, **40**:2066-2074.
38. Corringer PJ, Bertrand S, Galzi JL, Devillers-Thierry A, Changeux JP, Bertrand D: **Mutational analysis of the charge selectivity filter of the $\alpha 7$ nicotinic acetylcholine receptor.** *Neuron* 1999, **22**:831-843.
- This paper presents evidence that residues 234–238 of the $\alpha 7$ subunit constitute a critical loop that contributes to the charge selectivity filter of the channel, on the basis of single amino-acid replacements and the effect of an inserted proline residue either before, after or in the 234–238 loop.
39. Wilson GG, Karlin A: **The location of the gate in the acetylcholine receptor channel.** *Neuron* 1998, **20**:1269-1281.
40. Keramidas A, Moorhouse AJ, French CR, Schofield PR, Barry PH: **M2 pore mutations convert the glycine receptor channel from being anion- to cation-selective.** *Biophys J* 2000, **79**:247-259.
41. Doyle DA, Cabral JM, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R: **The structure of the potassium channel: molecular basis of K^{+} conduction and selectivity.** *Science* 1998, **280**:69-77.
42. England PM, Zhang Y, Dougherty DA, Lester HA: **Backbone mutations in transmembrane domains of a ligand-gated ion channel: implications for the mechanism of gating.** *Cell* 1999, **96**:89-98.
- This paper provides a ground-breaking approach to test the role of backbone hydrogen bonds, with significant effects noted for residues in the M2 putative channel-lining domain.
43. Miyazawa A, Fujiyoshi Y, Stowell M, Unwin N: **Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel wall.** *J Mol Biol* 1999, **288**:765-786.
- This paper reports progress in structural studies that are now approaching atomic resolution. Although still short of definitive conclusions on specific atomic features, a number of preliminary conclusions are presented that suggest possible experimental tests, particularly for the cytoplasmic domain.
44. Akk G, Steinbach JH: **Structural elements near the C-terminus are responsible for changes in nicotinic receptor gating kinetics following patch excision.** *J Physiol (Lond)* 2000, **527**:405-417.
45. Quiram PA, Ohno K, Milone M, Patterson MC, Pruitt NJ, Brengman JM, Sine SM, Engel AG: **Mutation causing congenital myasthenia reveals acetylcholine receptor beta/delta subunit interaction essential for assembly.** *J Clin Invest* 1999, **104**:1403-1410.
- This report describes a severe congenital myasthenic syndrome resulting from a deletion in the β subunit that results in curtailed receptor expression. Co-expression of the mutant gene with other subunits in 293 HEK cells is used to reveal that the mutation impairs interactions with the δ subunit.
46. Hucho F, Tsetlin VI, Machold J: **The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor.** *Eur J Biochem* 1996, **239**:539-557.
47. Jayaraman V, Usherwood PN, Hess GP: **Inhibition of nicotinic acetylcholine receptor by philanthotoxin-343: kinetic investigations in the microsecond time region using a laser-pulse photolysis technique.** *Biochemistry* 1999, **38**:11406-11414.
48. Wang HL, Ohno K, Milone M, Brengman JM, Evoli A, Batocchi AP, Middleton LT, Christodoulou K, Engel AG, Sine SM: **Fundamental gating mechanism of nicotinic receptor channel revealed by mutation causing a congenital myasthenic syndrome.** *J Gen Physiol* 2000, **116**:449-462.
49. Herz JM, Johnson DA, Taylor P: **Distance between the agonist and noncompetitive inhibitor sites on the nicotinic acetylcholine receptor.** *J Biol Chem* 1989, **264**:12439-12448.

50. Edelman SJ, Schaad O, Changeux JP: **Myasthenic nicotinic receptor mutant interpreted in terms of the allosteric model.** *C R Acad Sci Paris* 1997, **320**:953-961.
51. Ohno K, Hutchinson DO, Milone M, Brengman JM, Bouzat C, Sine SM, Engel AG: **Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ϵ subunit.** *Proc Natl Acad Sci USA* 1995, **92**:758-762.
52. Bertrand S, Devillers-Thiery A, Palma E, Buisson B, Edelman SJ, Corringer P-J, Changeux J-P, Bertrand D: **Paradoxical allosteric effects of competitive inhibitors on neuronal $\alpha 7$ nicotinic receptor mutants.** *Neuroreport* 1997, **8**:3591-3596.
53. Grosman C, Auerbach A: **Kinetic, mechanistic, and structural aspects of unliganded gating of acetylcholine receptor channels: a single-channel study of second transmembrane segment 12' mutants.** *J Gen Physiol* 2000, **115**:621-635.
- This paper reports unliganded opening probabilities and average lifetimes for wild-type and a series of mutant receptors involving various amino acids at the 12th position of the M2 transmembrane helix, demonstrating that unliganded openings must be taken into account in any complete analysis of the functional properties of nAChR.
54. Revah F, Bertrand D, Galzi J-L, Devillers-Thiery A, Mulle C, Hussy N, Bertrand S, Ballivet M, Changeux JP: **Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor.** *Nature* 1991, **353**:846-849.
55. Rajendra S, Lynch J, Pierce KD, French CR, Barry PH, Schofield PR: **Mutation of an arginine residue transforms β -alanine and taurine from agonists into competitive antagonists.** *Neuron* 1995, **14**:169-175.
56. Taverna F, Xiong ZG, Brandes L, Roder JC, Salter MW, MacDonald JF: **The Lurcher mutation of an α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit enhances potency of glutamate and converts an antagonist to an agonist.** *J Biol Chem* 2000, **275**:8475-8479.
- This paper shows that point mutations in glutamate receptors can produce pleiotropic phenotypes similar to the one first observed for the $\alpha 7$ nAChR receptor L247T mutation in the M2 domain that increases agonist affinity and converts competitive antagonists to partial agonists. The mutation responsible for the Lurcher mutation in GluR82 is incorporated at the homologous position in the GluR1 subunit, which lies in the M3 domain.
57. Xie Y, Cohen JB: **Contributions of *Torpedo* nicotinic acetylcholine receptor γ Trp-55 and δ Trp-57 to agonist and competitive antagonist function.** *J Biol Chem* 2001, **276**:2417-2426.
58. Edelman SJ, Schaad O, Changeux J-P: **Single bindings versus single channel recordings: a new approach to ionotropic receptors.** *Biochemistry* 1997, **36**:13755-13760.
59. Prince RJ, Sine SM: **Acetylcholine and epibatidine binding to muscle acetylcholine receptors distinguish between concerted and uncoupled models.** *J Biol Chem* 1999, **274**:19623-19629.
60. Krauss M, Korr D, Herrmann A, Hucho F: **Binding properties of agonists and antagonists to distinct allosteric states of the nicotinic acetylcholine receptor are incompatible with a concerted model.** *J Biol Chem* 2000, **275**:30196-30201.
61. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K: **Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.** *Nature* 2000, **407**:971-977.
- The structural studies presented in this article reveal 'active' and 'resting' conformations in dynamic equilibrium that are modulated through the dimeric interface by a packed α -helical structure.
62. Schlessinger J: **Cell signaling by receptor tyrosine kinases.** *Cell* 2000, **103**:211-225.
- A review of tyrosine receptor kinases that emphasizes the presence of an active dimer state that is stabilized by ligand binding.
63. Changeux J-P, Thiery J-P, Tung T, Kittel C: **On the cooperativity of biological membranes.** *Proc Natl Acad Sci USA* 1967, **57**:335-341.
64. Schindler H, Spillecke F, Neumann E: **Different channel properties of *Torpedo* acetylcholine receptor monomers and dimers reconstituted in planar membranes.** *Proc Natl Acad Sci USA* 1984, **81**:6222-6226.
65. Yeramian E, Trautmann A, Claverie P: **Acetylcholine receptors are not functionally independent.** *Biophys J* 1986, **50**:253-263.
66. Schmidt EK, Liebermann T, Kreiter M, Jonczyk A, Naumann R, Offenhausser A, Neumann E, Kukol A, Maelicke A, Knoll W: **Incorporation of the acetylcholine receptor dimer from *Torpedo californica* in a peptide supported lipid membrane investigated by surface plasmon and fluorescence spectroscopy.** *Biosens Bioelectron* 1998, **13**:585-591.
67. Duke TA, Bray D: **Heightened sensitivity of a lattice of membrane receptors.** *Proc Natl Acad Sci USA* 1999, **96**:10104-10108.
- This article and others cited therein further develop the theory [63] for super-cooperativity of clustered receptors.
68. Qian D, Weiss A: **T cell antigen receptor signal transduction.** *Curr Opin Cell Biol* 1997, **9**:205-212.
69. Sharma MR, Penczek P, Grassucci R, Xin HB, Fleischer S, Wagenknecht T: **Cryo-electron microscopy and image analysis of the cardiac ryanodine receptor.** *J Biol Chem* 1998, **273**:18429-18434.
70. Oghalai JS, Patel AA, Nakagawa T, Brownell WE: **Fluorescence-imaged microdeformation of the outer hair cell lateral wall.** *J Neurosci* 1998, **18**:48-58.
71. Khakh BS, Zhou X, Sydes J, Galligan JJ, Lester HA: **State-dependent cross-inhibition between transmitter-gated cation channels.** *Nature* 2000, **406**:405-410.
- Studies using synaptically coupled myenteric neurons reveal that nicotinic fast excitatory postsynaptic currents are occluded during activation of endogenously co-expressed P2X channels.
72. Engel AG, Ohno K, Sine SM: **Congenital myasthenic syndromes: recent advances.** *Arch Neurol* 1999, **56**:163-167.
73. Milone M, Wang HL, Ohno K, Prince R, Fukudome T, Shen XM, Brengman JM, Griggs RC, Sine SM, Engel AG: **Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor ϵ subunit.** *Neuron* 1998, **20**:575-588.
74. Wang HL, Milone M, Ohno K, Shen XM, Tsujino A, Batocchi AP, Tonali P, Brengman J, Engel AG, Sine SM: **Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating.** *Nat Neurosci* 1999, **2**:226-233.
75. Steinlein OK: **Neuronal nicotinic receptors in human epilepsy.** *Eur J Pharmacol* 2000, **393**:243-247.
76. Fusco MD, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G: **The nicotinic receptor $\beta 2$ subunit is mutant in nocturnal frontal lobe epilepsy.** *Nat Genet* 2000, **26**:275-276.
77. Sekhon HS, Jia Y, Raab R, Kuryatov A, Pankow JF, Whitsett JA, Lindstrom J, Spindel ER: **Prenatal nicotine increases pulmonary $\alpha 7$ nicotinic receptor expression and alters fetal lung development in monkeys.** *J Clin Invest* 1999, **103**:637-647.
78. Sweatt JD, Bui D, W PJ, Dineley KT: **$\alpha 7$ is upregulated in the TG2576 mouse model of Alzheimer's disease.** *Soc Neurosci Abstr* 2000, **25**:419.
79. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB: **β -Amyloid(1-42) binds to $\alpha 7$ nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.** *J Biol Chem* 2000, **275**:5626-5632.
80. Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris JG, Nagamoto HT, Olincy A, Ross RG, Stevens KE *et al.*: **Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia.** *Am J Med Genet* 2000, **97**:58-64.
81. Silverman MA, Neale MC, Sullivan PF, Harris-Kerr C, Wormley B, Sadek H, Ma Y, Kendler KS, Straub RE: **Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNA2) gene show no association with smoking initiation or nicotine dependence.** *Am J Med Genet* 2000, **96**:646-653.
82. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP: **Nicotinic receptor function: new perspectives from knockout mice.** *Trends Pharmacol Sci* 2000, **21**:211-217.
83. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux JP: **Reduced antinociception in mice lacking neuronal nicotinic receptor subunits.** *Nature* 1999, **398**:805-810.
- Homozygous $\alpha 4^{-/-}$ mice, which no longer express high-affinity nicotine- and epibatidine-binding sites throughout the brain, exhibit a reduced anti-nociceptive effect of nicotine on the hot-plate test and diminished sensitivity to nicotine in the tail-flick test, as do mice lacking $\beta 2$.

84. Ross SA, Wong JY, Clifford JJ, Kinsella A, Massalas JS, Horne MK, Scheffer IE, Kola I, Waddington JL, Berkovic SF, Drago J: **Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse.** *J Neurosci* 2000, 20:6431-6441.
85. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP: **Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.** *Nature* 1998, 391:173-177.
86. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP: **Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors.** *EMBO J* 1999, 18:1235-1244.
87. Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou CN, Patrick J, Role L, De Biasi M, Beaudet AL: **Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor.** *Proc Natl Acad Sci USA* 1999, 96:5746-5751.
88. Xu W, Orr-Urtreger A, Nigro F, Gelber S, Sutcliffe CB, Armstrong D, Patrick JW, Role LW, Beaudet AL, De Biasi M: **Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors.** *J Neurosci* 1999, 19:9298-9305.
89. Ragozzino D, Monaco L, Mileo AM, Mattei E, Giovannelli A, Maggi L, Castellano C, Cestari V, Ciamei A, Ciotti MT *et al.*: **Emotional memory impairment in transgenic mice with a mutant form of the nicotinic receptor alpha7 subunits.** *Soc Neurosci Abstr* 2000, 25:526.
90. Labarca C, Deshpande P, Schwarz J, Schwarz S, Khakh BS, Kofuji P, Nowak M, Dang H, Chen Z, Boulter J *et al.*: **Knockin mice with hypersensitive neuronal nicotinic receptors.** *Soc Neurosci Abstr* 2000, 25:526.
91. Paterson D, Nordberg A: **Neuronal nicotinic receptors in the human brain.** *Prog Neurobiol* 2000, 61:75-111.
92. Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, Sullivan JP: **Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha4beta2 receptor.** *J Pharmacol Exp Ther* 1996, 276:289-297.
93. Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J: **Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y.** *Mol Pharmacol* 1997, 51:776-784.
94. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, Lindstrom J: **Chronic nicotine treatment up-regulates human alpha3beta2 but not alpha3beta4 acetylcholine receptors stably transfected in human embryonic kidney cells.** *J Biol Chem* 1998, 273:28721-28732.
95. Fenster CP, Whitworth TL, Sheffield EB, Quick MW, Lester RA: **Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.** *J Neurosci* 1999, 19:4804-4814.
96. Whiteaker P, Sharples CG, Wonnacott S: **Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.** *Mol Pharmacol* 1998, 53:950-962.
97. Reitsstetter R, Lukas RJ, Gruener R: **Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure.** *J Pharmacol Exp Ther* 1999, 289:656-660.
- Desensitization studies are described on muscle-type nicotinic acetylcholine receptors in TE671/RD cells. The recovery from nicotine-induced desensitization is consistently faster than the recovery from acetylcholine-induced desensitization regardless of whether nicotine or acetylcholine is used to assess levels of desensitization, suggesting that more than one desensitized state of the receptor can occur and that nicotinic agonists vary in their efficiency of inducing receptors to states of differing depths of desensitization.
98. Green WN: **Ion channel assembly: creating structures that function.** *J Gen Physiol* 1999, 113:163-170.
99. Keller SH, Taylor P: **Determinants responsible for assembly of the nicotinic acetylcholine receptor.** *J Gen Physiol* 1999, 113:171-176.
100. Bertrand D, Changeux JP: **Nicotinic receptor: a prototype of allosteric ligand-gated ion channels and its possible implications in epilepsy.** *Adv Neurol* 1999, 79:171-188.
101. Marubio LM, Changeux JP: **Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function.** *Eur J Pharmacol* 2000, 393:113-121.
102. Dehaene S, Kerszberg M, Changeux JP: **A neuronal model of a global workspace in effortful cognitive tasks.** *Proc Natl Acad Sci USA* 1998, 95:14529-14534.
103. Changeux J-P: **Sur les propriétés allostériques de la L-thréonine et de la L-leucine sur la L-thréonine désaminase. VI. Discussion générale.** *Bull Soc Chim Biol* 1965, 47:281-300.
104. Wilson G, Karlin A: **Acetylcholine receptor channel structure in the resting, open, and desensitized states probed with the substituted-cysteine-accessibility method.** *Proc Natl Acad Sci USA* 2001, 98:1241-1248.
105. Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, Nashmi R, Kofuji P, Dang H, Shi W *et al.*: **Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety.** *Proc Natl Acad Sci USA* 2001, 98:2786-2791.
106. Liu QS, Kawai H, Berg DK: **Beta-Amyloid peptide blocks the response of alpha7-containing nicotinic receptors on hippocampal neurons.** *Proc Natl Acad Sci USA* 2001, in press.
107. Pettit DL, Shao Z, Yakel JL: **Beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.** *J Neurosci* 2001, 21:RC210.
108. Buisson B, Bertrand D: **Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function.** *J Neurosci* 2001, 21:1819-1829.
109. Perry E, Walker M, Grace J, Perry R: **Acetylcholine in mind: a neurotransmitter correlate of consciousness?** *Trends Neurosci* 1999, 22:273-280.

Now in press

The works referred to in the main text as (Brejc *et al.*, personal communication), and (Smit *et al.*, personal communication), have now been published (as [110,111] respectively).

110. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J, Smit AB, Sixma TK: **Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.** *Nature* 2001, 411:269-276.
111. Smit AB, Syed NI, Schaap D, van Minnen J, Klumperman J, Kits KS, Lodder HC, van der Schors RC, van Elk R, Sorgedrager B *et al.*: **A glia-derived acetylcholine-binding protein that modulates synaptic transmission.** *Nature* 2001, 411:261-268.